Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab

OBJECTIVES: Primary * To determine the proportion of patients who are free from progression at 12 weeks from the start of second-line therapy. Secondary * To determine objective response rate. * To determine overall survival. * To further define the dosing and safety profile of irinotecan hydrochloride and cediranib. OUTLINE: This is a multicenter study. Patients receive irinotecan hydrochloride IV over 90 minutes on days 1 and 8 and oral cediranib once daily on days 1-21. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. After completion of study therapy, patients are followed up every 3 months for up to 2 years from study entry.